department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Context Therapeutics Inc. ($CNTX) · pharmadog

PUBLIC COMPANY

$CNTXContext Therapeutics Inc.

Philadelphia, PA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Phase 1

Bile Duct Cancer (Cholangiocarcinoma)

Endometrial Cancer

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Context Therapeutics Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$CNTX

SEC CIK

0001842952

country

US

source

sec_tickers

top tags

NSCLC2 Oncology2 Colorectal Cancer1

mentioned in

0news items

entity-linker matched

$CNTX

Active trials

phase1CT-95 in Advanced Cancers Associated With Mesothelin Expressionrecruitingn=70
phase1A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancersnot yet recruitingn=162
phase1A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumorsrecruitingn=80
phase2Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancerterminatedn=4
phase2A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancerwithdrawn

Data sources

last refreshed 13m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

routine RSU / option mechanics (4)

Feb 19, 26grantLevit Alex C. · Chief Legal Officer, Corp. Sec270,000 sh
Feb 19, 26grantMinai-Azary Jennifer Lynn · Chief Financial Officer275,000 sh
Feb 19, 26grantChagin Karen Deborah · Chief Medical Officer290,000 sh
Feb 19, 26grantLehr Martin A. · Chief Executive Officer815,000 sh